Search research articles
Contact Us
Filters
Showing results (81-90 of 324) with videos related to
Page
of 33
Sort By:
The Oncologist
|
April 30, 2010
Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups
Tejal A Patel, Gerardo Colon-Otero, Celyne Bueno Hume, et al.
Breast Cancer Research and Treatment
|
June 16, 2009
Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization
Joseph A Sparano, Gabriel N Hortobagyi, Julie R Gralow, et al.
Mayo Clinic Proceedings
|
June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
Edith A Perez, Maria Koehler, Julie Byrne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
Pooja P Advani, Karla V Ballman, Travis J Dockter, et al.
Cancer
|
June 19, 2013
Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
Louis P Garrison, Deepa Lalla, Melissa Brammer, et al.
Cancer Investigation
|
March 20, 2003
Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies
Edith A Perez, David R Gandara, Martin J Edelman, et al.
Molecular Cancer Therapeutics
|
April 9, 2015
Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101
Sahra Borges, Edith A Perez, E Aubrey Thompson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 13, 2019
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Louis P Garrison, Joseph Babigumira, Clément Tournier, et al.
Nature Reviews. Clinical Oncology
|
November 30, 2011
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L Arteaga, Mark X Sliwkowski, C Kent Osborne, et al.
The Journal of Cell Biology
|
November 19, 2008
p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression
Edwin Soto, Masahiro Yanagisawa, Laura A Marlow, et al.
Page
of 33
Search research articles
Search
Showing results (81-90 of 324) with videos related to
Sort By:
Page
of 33
The Oncologist
|
April 30, 2010
Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups
Tejal A Patel, Gerardo Colon-Otero, Celyne Bueno Hume, et al.
Breast Cancer Research and Treatment
|
June 16, 2009
Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization
Joseph A Sparano, Gabriel N Hortobagyi, Julie R Gralow, et al.
Mayo Clinic Proceedings
|
June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
Edith A Perez, Maria Koehler, Julie Byrne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
Pooja P Advani, Karla V Ballman, Travis J Dockter, et al.
Cancer
|
June 19, 2013
Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
Louis P Garrison, Deepa Lalla, Melissa Brammer, et al.
Cancer Investigation
|
March 20, 2003
Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies
Edith A Perez, David R Gandara, Martin J Edelman, et al.
Molecular Cancer Therapeutics
|
April 9, 2015
Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101
Sahra Borges, Edith A Perez, E Aubrey Thompson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 13, 2019
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
Louis P Garrison, Joseph Babigumira, Clément Tournier, et al.
Nature Reviews. Clinical Oncology
|
November 30, 2011
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L Arteaga, Mark X Sliwkowski, C Kent Osborne, et al.
The Journal of Cell Biology
|
November 19, 2008
p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression
Edwin Soto, Masahiro Yanagisawa, Laura A Marlow, et al.
Page
of 33